Drawing for PRECIGEN

USPTO serial 87366798

PRECIGEN

Reviewed by CopyMark Law Group

Reg. 7026015Status 700Registered
Filing date
Status date
Registration date
Apr 11, 2023
Examiner
HUDSON, TAMARA BREE
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with PRECIGEN?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

David R. Kelly

David R. Kelly Barnes & Thornburg LLP3475 Piedmont Road NEAtlanta, GA 30305UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001Chemicals, biochemicals and reagents for use in industry and science; chemicals, biochemicals and reagents, namely, proteins for regulating, modifying or restricting gene expression; kits consisting primarily of proteins for regulating, modifying or restricting gene expressionACTIVE—
005Chemical preparations for medical and veterinary purposes, namely, for gene and cell therapy for treating genetic disorders, cancers, rare diseases, infectious diseases, and cardiovascular and immunological diseases and disorders; biochemical preparations for medical and veterinary purposes, namely, for gene and cell therapy for treating genetic disorders, cancers, rare diseases, infectious diseases, and cardiovascular and immunological diseases and disorders; chemical reagents for medical and veterinary purposes, namely, for gene and cell therapy for treating genetic disorders, cancers, rare diseases, infectious diseases, and cardiovascular and immunological diseases and disordersACTIVE—
042Scientific research and development services in the field of medicine, pharmacology, immunology, biochemistry, cell biology, genetics, microbiology and virology; Scientific research in the field of healthcare; Therapeutic research of treatments in the fields of oncology, rare diseases, metabolic disorders, infectious diseases, ophthalmology, and cardiovascular disease which are under development or have completed development; Development of products being genetic therapies, biopharmaceuticals, and effectors to regulate, modulate, and characterize disease states; Development of tools in the nature of software and biotechnological processes to regulate, modulate, and characterize disease states; Research and development services for others in the field of biotechnology, namely, genetically engineering DNA, biological organisms, cells, viruses, pathogens, and special purpose cells for scientific, research, medical and laboratory use; Research and development services for others in the fields of genetics and biotechnology, namely, genetically engineering DNA, biological organisms, cells, viruses, pathogens, and special purpose cells for scientific, research, medical and laboratory useACTIVEJan 1, 2018
044Medical services; Medical services, namely, genetic engineering, biopharmaceuticals and gene therapy services; Healthcare services, namely, treatment of patients with genetic disorders, cancers, rare diseases, infectious diseases, and cardiovascular and immunological diseases and disorders; Medical services, namely, providing medical therapy treatments which are under development or have completed development for patients in the fields of oncology, rare diseases, metabolic disorders, infectious diseases, ophthalmology, and cardiovascular diseasesACTIVEJan 1, 2018
045Technology transfer services, namely, licensing of intellectual propertyACTIVEJan 1, 2018

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 24, 2025ASCKASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY—
Feb 7, 2024ASCKASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY—
Feb 7, 2024ASCKASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY—
Apr 11, 2023NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Apr 11, 2023R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Mar 7, 2023SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Mar 6, 2023CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Feb 23, 2023TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Feb 23, 2023CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 23, 2023TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 13, 2022GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 13, 2022GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 13, 2022CNRTSU - NON-FINAL ACTION - WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 19, 2022SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Oct 17, 2022IUAFUSE AMENDMENT FILED—
Oct 17, 2022EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
May 31, 2022CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
May 31, 2022TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
May 31, 2022ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 31, 2022REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
May 31, 2022COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Apr 12, 2022EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Apr 11, 2022EX5GSOU EXTENSION 5 GRANTED—
Apr 8, 2022EXT5SOU EXTENSION 5 FILED—
Apr 8, 2022EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Oct 22, 2021EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 20, 2021EX4GSOU EXTENSION 4 GRANTED—
Oct 20, 2021EXT4SOU EXTENSION 4 FILED—
Oct 20, 2021EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 22, 2021EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Apr 20, 2021EX3GSOU EXTENSION 3 GRANTED—
Apr 20, 2021EXT3SOU EXTENSION 3 FILED—
Apr 20, 2021EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Oct 24, 2020EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 22, 2020EX2GSOU EXTENSION 2 GRANTED—
Oct 22, 2020EXT2SOU EXTENSION 2 FILED—
Oct 22, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 11, 2020EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Apr 10, 2020EX1GSOU EXTENSION 1 GRANTED—
Apr 10, 2020AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Apr 8, 2020EXT1SOU EXTENSION 1 FILED—
Apr 8, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 8, 2020ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Oct 22, 2019NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Aug 27, 2019NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Aug 27, 2019PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 7, 2019NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jul 19, 2019ALIEASSIGNED TO LIE—
Jul 10, 2019CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Dec 21, 2018RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Jun 21, 2018RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Dec 21, 2017GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Dec 21, 2017GNSLLETTER OF SUSPENSION E-MAILED—
Dec 21, 2017CNSLSUSPENSION LETTER WRITTEN—
Dec 6, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Dec 5, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 5, 2017TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 5, 2017GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 5, 2017GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 5, 2017CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 5, 2017DOCKASSIGNED TO EXAMINER—
Mar 16, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 14, 2017NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance